Webinar
On-Demand Webinar: From Pre-Approval Inspection (PAI) to Complete Response Letter (CRL). Watch Now →
On-Demand Webinar: From Pre-Approval Inspection (PAI) to Complete Response Letter (CRL). Watch Now →
Products
products
Regulatory Intelligence
Understand and act on global regulatory change.
Inspection Intelligence
Anticipate inspection focus and enforcement risk.
Site Intelligence
Evaluate site and supplier risk.
Post-market Intelligence
Detect product quality & safety signals.
platform & data
Redica App
Instant insights on the platform.
Integrated solutions
End-to-end connected intelligence.
API
Real-time, scalable data access.
Our Data
Globally-trusted quality data & insights.
Explore integrations
Solutions
by function
Quality Teams
Regulatory Compliance
Supply Chain
Regulatory Affairs
Digital IT Teams
by industry
Pharmaceutical
MedTech
Cosmetics
Supplements & OTC
Food
Financial Services
featured case study
How a Top 10 Pharma Company Transformed CMO and API Oversight
latest report
Report – Strategic PAI Readiness: A Data-Driven Approach for Pharma Sponsors and Manufacturers
Resources
resources by type
Assessments
Insights on inspections, risk, and compliance.
Blog
Evaluate readiness and compliance maturity.
Reports
Benchmark industry trends and best practices.
Webinars
Hear from industry leaders and Redica experts.
latest report
Report – Strategic PAI Readiness: A Data-Driven Approach for Pharma Sponsors and Manufacturers
Quick links
Document Store
Knowledge Center
Login
Contact us
Company
Login
book a demo
Login
book a demo
Home
/
Blog
/
FDA inspection
FDA inspection
Trends
FDA Increased For-Cause Inspections Almost 250% in 2025
November 12, 2025
Conference Spotlight
A Glimpse into the Thought Processes of an FDA Expert Investigator
August 28, 2024
Conference Spotlight
FDA on the Evolution of Biologics Inspections: Part III
January 26, 2023
Conference Spotlight
Who Decides if my FDA Inspection is Classified OAI?
September 29, 2022
Where is My EIR?
September 20, 2022
Conference Spotlight
FDA on Compliance Issues in Pharma
September 16, 2022
Redica Responds: How Many GMP Inspections Have Resulted in a 483?
September 14, 2022
Redica Responds: Top Quality Systems Issues at Medical Device Sites
August 31, 2022
Conference Spotlight
From Data Integrity to Data Culture
July 21, 2022
A Short Guide to GMP Process Validation
July 19, 2022
What Can Trigger a CAPA?
July 5, 2022
What is GMP Compliance? A Complete 2025 Guide
June 21, 2022
Conference Spotlight
Perforated Tables in Cleanrooms Draw FDA Attention
June 2, 2022
All tags
101
2011 process validation guidance
2022 PDA Annual Meeting
2024 highlights
483
483 Findings
483 Response Letter
483 observation
483 observations
483 response
503A
503B
503B outsourcing
510k
510k submission
AI
AI-Powered
ALCOA
ALCOA-C,
ANMAT
APAC
APAC
API
API Manufacturer
Alison Sathe
Anne Johnson
Argentina
Asia-Pacific
Audit
BIMO
BLAs
Biologics
Bob McDowall
CAPA
CAPA System
CBER
CDER
CDER Updates
CDMO
CFR
CGMP
CGT
CMC
CMO
COFEPRIS
CPAP Machines
CPO
CROs
CVM
Case Study
Catalyst
Cell and Gene
China
Clinical Trial Guidance
Code of Federal Regulations
Colombia
Combination Products
Combination Products
Comparison report
Compliance
ConOps
Contamination
Context Engineering
Contract Facilities
Cost of Quality
DCT
DEG
DEG-contaminated
DEG/EG
DIGEMID
DOJ
DaaS
Data Enrichment
Data Explorer
Data Falsification
Data Governance
Data Ingegrity
Data Integrity
Data Manipulation
Data Operations
Data Sources
Data integirty
Data-as-a-service
Devices
Devies
Digital IT Teams
Document Store
Donald Ashley
Draft Guidance
Drug Approval
Drug Approvals
Drug Manufacturing
Drug Shortages
Drug Shortages
Drug recalls
Dupont
EG
EIR
EIRs
EMA
Next
1 / 4